Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 22, Issue 26, Pages 3996-4010Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666160520115248
Keywords
Alzheimer's Disease; metal ions; metal complexes; AD drugs; anti-A beta aggregating agents; imaging
Categories
Funding
- Mahlke-Obermann Stiftung
- European Union [609431]
Ask authors/readers for more resources
Background: Alzheimer's disease (AD) is the most common form of dementia that seriously affects daily life. Even if AD pathogenesis is still subject of debate, it is generally accepted that cerebral cortex plaques formed by aggregated amyloid-beta (A beta) peptides can be considered a characteristic pathological hallmark. It is well known that metal ions play an important role in the aggregation process of A beta. Methods: This review focuses on the anti-A beta aggregation activity of chelating ligands as well as on the use of metal complexes as diagnostic probes and as potential drugs. Conclusion: While chelating agents, such as curcumin or flavonoid derivatives, are currently used to capture metal ions responsible for A beta aggregation, the potential application of platinum, ruthenium and cobalt complexes, among others, of several heterocyclic ligands, represents a promising new strategy to fight AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available